Phaseline

Targets › FLT3

FLT3 (Receptor-type tyrosine-protein kinase FLT3): drug programs, companies and trials

42 programs from 38 companies in 133 trials: 58 Phase 2, 56 Phase 1, 19 Phase 3; Oncology, Gastroenterology, Hematology; next expected readout Nov 2026.

Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. (UniProt, P36888)

Open in Phaseline: the race on FLT3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai Jiao Tong University School of MedicineFludarabine, Busulfan and Melphalan (Flu-Bu-Mel)
Dual alkylating agents with purine nucleoside analog; busulfan and melphalan are DNA-alkyl
FLT3, TP53Phase 3Acute Myeloid Leukemia; ToxicitiesDec 2026
Swedish Orphan BiovitrumPacritinib
Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Activin receptor type-1 inhibitor
JAK2, FLT3, ACVR1, IRAK1Phase 3Primary Myelofibrosis; VEXAS; Myelofibrosis; Acute Myeloid Leukemia …Dec 2026
Daiichi SankyoPexidartinib
Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor
CSF1R, FLT3, KITPhase 3Tenosynovial Giant Cell Tumor; Neurofibroma, PlexiformMar 2027
Daiichi SankyoQuizartinib
Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor
CSF1R, FLT3, KIT, PDGFRB, PDGFRAPhase 3Leukemia; Acute Myeloid Leukemia; Hepatic Impairment; Acute Myeloid Leukemia, Adult …May 2027
Jiangsu HengRui MedicineFamitinib
Stem cell growth factor receptor inhibitor; Vascular endothelial growth factor receptor 1 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
KIT, FLT1, FLT3, PDGFRB, PDGFRAPhase 3Cervical Cancer; Triple-Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Breast Neoplasm …May 2027
Sunshine Lake PharmaClifutinib Besylate (HEC73543)
FLT3-ITD inhibitor
FLT3Phase 3Leukemia, Acute Myeloid (AML); Acute Myeloid Leukemia, AdultNov 2027
RocheSorafenib
Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor
RAF1, PDGFRB, KIT, FLT3, BRAFPhase 3Unresectable Hepatocellular Carcinoma; AML (Acute Myeloid Leukemia); Locally Advanced Thyroid Gland Carcinoma; Hepatocellular Carcinoma …–
M.D. Anderson Cancer CenterSunitinib Malate
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Renal Cell Carcinoma; Malignant Neoplasms of Urinary Tract; Prostate CancerDec 2026
National Cancer Institute (NCI)Sunitinib Malate
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Advanced Lymphoma; Metastatic Pancreatic Neuroendocrine TumorDec 2026
Ryvu TherapeuticsMEN1703 (SEL24, Dapolsertib hydrochloride)
Dual inhibitor of PIM kinases and FLT3
PIM1, PIM2, PIM3, FLT3Phase 2Non-Hodgkin Lymphoma, B-cellDec 2026
Nanfang Hospital, Southern Medical UniversityDonafenib
multi-targeted tyrosine kinase inhibitor
BRAF, FLT3, RETPhase 2Unresectable Hepatocellular CarcinomaDec 2026
Weill Medical College of Cornell UniversityCDX-301
Tyrosine-protein kinase receptor FLT3 agonist
FLT3Phase 2Breast CancerDec 2026
Canadian Cancer Trials GroupSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Advanced Rare TumoursDec 2026
University of MiamiSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Gastrointestinal Stromal TumorsDec 2026
National Cancer Institute (NCI)Sorafenib Tosylate
Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor
RAF1, PDGFRB, KIT, FLT3, BRAFPhase 2Gastrointestinal Stromal Tumor; Acute Myeloid Leukemia; Advanced Malignant Solid NeoplasmMar 2027
Sarcoma Alliance for Research through CollaborationSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Gastrointestinal Stromal TumorsJun 2027
Fudan UniversitySitravatinib
Small molecule inhibitor of receptor tyrosine kinases
PDGFRA, KIT, RET, FLT3Phase 2Metastatic Breast CancerJun 2027
American Society of Clinical OncologySunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Lymphoma, Non-HodgkinDec 2027
Bai-Rong XiaSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Ovary CancerDec 2027
Memorial Sloan Kettering Cancer CenterSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2OsteosarcomaMar 2028
TheradexPacritinib
Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Activin receptor type-1 inhibitor
JAK2, FLT3, ACVR1, IRAK1Phase 2Leukemia, Myelomonocytic, ChronicJul 2028
NovartisMidostaurin
Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor
FLT3, KIT, PDGFRB, PDGFRA, PRKD3Phase 2FLT3-mutated Acute Myeloid Leukemia; AML/MDS; Acute Myeloid LeukemiaMay 2029
Yu WangDonafenib
Multikinase inhibitor targeting BRAF, VEGFR, and FLT3
BRAF, VEGFR, FLT3Phase 2Thyroid Cancer–
West China HospitalDonafenib
Multi-targeted tyrosine kinase inhibitor targeting RAF, VEGFR, and FLT3
RAF, VEGFR, FLT3Phase 2Locally Advanced Thyroid Gland Carcinoma–
Aptose BiosciencesTuspetinib (HM43239)
FLT3 inhibitor
FLT3Phase 1Leukemia, Myeloid, AcuteNov 2026
Bristol-Myers SquibbFedratinib
Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor
FLT3, JAK2Phase 1Primary Myelofibrosis; Acute Myeloid LeukemiaNov 2026
Emory UniversityMRX-2843
FLT3/MerTK inhibitor
FLT3, MERTKPhase 1Advanced Lung Non-Small Cell CarcinomaDec 2026
University of Southern CaliforniaCDX-301
Tyrosine-protein kinase receptor FLT3 agonist
FLT3Phase 1Anatomic Stage IV Breast Cancer AJCC v8Jan 2027
Hemogenyx PharmaceuticalsAnti-FLT3 CAR-T cells
Anti-FLT3 chimeric antigen receptor T-cell therapy
FLT3Phase 1Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)Jan 2027
Ashutosh Kumar TewariCDX-301
Tyrosine-protein kinase receptor FLT3 agonist
FLT3Phase 1Prostate CancerJan 2027
Etnova TherapeuticsETN101
Multiple tyrosine kinase inhibitor targeting FLT3, KIT, VEGFR2, and PDGFRB
FLT3, KIT, VEGFR2, PDGFRBPhase 1Hepatocellular CarcinomaMar 2027
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyTAA05 Cell Injection
Anti-FLT3 CAR-T cell therapy
FLT3Phase 1Acute Myeloid LeukemiaJun 2027
Hangzhou Polymed BiopharmaceuticalsHPB-092
FLT3 and IRAK4 inhibitor
FLT3, IRAK4Phase 1Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)Jun 2027
State University of New York at BuffaloSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 1Carcinoma, Renal CellJul 2027
University of Colorado, DenverSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 1OsteosarcomaAug 2027
Dana-Farber Cancer InstituteCDX-301
Tyrosine-protein kinase receptor FLT3 agonist
FLT3Phase 1MelanomaDec 2027
Rabin Medical CenterSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 1Solid Tumors Refractory to Standard TherapyJan 2028
University of Texas Southwestern Medical CenterCDX-301
Tyrosine-protein kinase receptor FLT3 agonist
FLT3Phase 1HER2-negative Breast CancerApr 2028
AstellasGilteritinib
Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase receptor UFO inhibitor
FLT3, AXLPhase 1Acute Myeloid Leukemia (AML); Non-small Cell Lung Cancer (NSCLC); AML (Acute Myeloid Leukemia); Acute Myeloid Leukemia …Jul 2028
National Cancer Institute (NCI)Zotiraciclib
Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 7 inhibitor
CDK1, CDK2, CDK7, CDK9, FLT3Phase 1Brain TumorAug 2028
Cullinan TherapeuticsCLN-049
FLT3 x CD3 bispecific T cell engager
FLT3, CD3EPhase 1Relapsed/Refractory Acute Myeloid Leukemia (AML)Dec 2029
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyFuruitinib
FLT3 inhibitor
FLT3Phase 1Advanced Malignancies–

Conditions

Acute Myeloid Leukemia (22) Hepatocellular Carcinoma (5) Primary Myelofibrosis (3) Prostate Cancer (3) Acute Myeloid Leukemia (AML) (3) Acute Myeloid Leukemia, Adult (2) Chronic Myelomonocytic Leukemia (2) Osteosarcoma (2) Thyroid Cancer (2) Myelofibrosis (2) Breast Cancer (2) Gastrointestinal Stromal Tumors (2)

Modalities

small molecule (25), mixed (10), antibody (4), other (2), protein or peptide (1)

Companies

National Cancer Institute (NCI) (3) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) Daiichi Sankyo (2) Sunshine Lake Pharma (1) Ryvu Therapeutics (1) Canadian Cancer Trials Group (1) Bristol-Myers Squibb (1) University of Texas Southwestern Medical Center (1) Novartis (1) Cullinan Therapeutics (1) Dana-Farber Cancer Institute (1) Aptose Biosciences (1) University of Southern California (1) Fudan University (1) Etnova Therapeutics (1) Memorial Sloan Kettering Cancer Center (1) Ashutosh Kumar Tewari (1) Yu Wang (1) Swedish Orphan Biovitrum (1) Emory University (1)

Related targets

KIT (19) PDGFRB (17) PDGFRA (15) CSF1R (13) BRAF (4) JAK2 (3) RAF1 (2) RET (2) VEGFR (2) ACVR1 (2) IRAK1 (2) PIM1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.